Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Roer

Adolescent Medicine Dayton, OH Medical Doctor

NPI 1396821518 CMS profile 244520

9350 Patriot Woods Ct, Dayton, OH 45458

Open in the dashboard

General payments

$18,687

199 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Roer of Dayton, OH is reported in the CMS Open Payments database as having received $18,687 across 199 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Adolescent Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $84 4
2024 General $8,020 31
2023 General $271 18
2022 General $604 26
2021 General $1,813 29
2020 General $7,299 57
2019 General $596 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Roer
  • Adolescent Medicine median
  • Middle half of Adolescent Medicine
  • National median

In program year 2025, general payments to David Roer were reported at $84. Among 914 Adolescent Medicine profiles paid that year, the median was $100 and the middle half received between $40 and $207.

Show as a table
Year David Roer Adolescent Medicine median Middle half National median
2019 $596 $95 $36–$198 $163
2020 $7,299 $50 $23–$111 $114
2021 $1,813 $67 $27–$179 $132
2022 $604 $79 $29–$189 $149
2023 $271 $100 $39–$194 $160
2024 $8,020 $93 $38–$195 $164
2025 $84 $100 $40–$207 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Genentech USA, Inc. $8,166 19 payments
  2. Verrica Pharmaceuticals Inc. $7,658 10 payments
  3. Merck Sharp & Dohme Corporation $425 26 payments
  4. Ironshore Pharmaceuticals Inc. $395 24 payments
  5. kaleo, Inc. $320 18 payments
  6. Corium, Inc. $304 19 payments
  7. GlaxoSmithKline, LLC. $300 14 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $253 18 payments
  9. Pfizer Inc. $196 11 payments
  10. Sanofi Pasteur Inc. $161 9 payments
  11. Other $508 31 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $10,770 8 payments
  2. Food and Beverage $3,503 182 payments
  3. Consulting Fee $2,730 1 payment
  4. Travel and Lodging $1,684 8 payments
Products named General payments · program years 2019–2025
  1. Xofluza $8,166 19 payments
  2. YCANTH $7,658 10 payments
  3. GARDASIL 9 $366 22 payments
  4. JORNAY PM $315 19 payments
  5. Azstarys $304 19 payments
  6. BEXSERO $300 14 payments
  7. AUVI-Q $235 17 payments
  8. VAXELIS $223 13 payments
  9. VYVANSE $182 12 payments
  10. EUCRISA $165 9 payments
  11. Other $2,045 122 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

199 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Adolescent Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record